Will the FDA approve imlifidase for kidney transplantation at its December 19 review?

Question

This market resolves YES if the US Food and Drug Administration grants marketing approval to imlifidase for enabling kidney transplantation in highly sensitised adult patients under the application with a target action date of December 19, 2026. Approval must authorise a therapeutic transplantation indication in the United States; an approval in another jurisdiction does not count.

A narrower eligible population, a requirement for specified donor compatibility testing, a risk-management program

Problyx · Accepted Answer

Yes — the community forecast puts this at 77%.

Problyx · Answer

No — the community forecast puts this at 23%.